Importantly, the current study for the first time provides clear evidence of highly reproducible lung functional, biochemical, and histological therapeutic effects of a TGFβR1/ALK5 inhibitor, based on outcomes of six individual intervention studies, establishing ALK5i as a reliable reference drug in preclinical drug discovery for IPF. This evidence concerns the gene TGFBR1 and idiopathic pulmonary fibrosis.